 |
|
|
| |
A Randomized Controlled Trial of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 12 Weeks in Genotype 2 HCV-Infected Patients:
The Phase 3 ASTRAL-2 Study
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Mark Sulkowski1, Norbert Bräu2, Eric Lawitz3, Mitchell L. Shiffman4, William J. Towner5, Peter Ruane6, Brian Doehle7, Jing Wang7, John McNally7, Anu Osinusi7, Diana M. Brainard7, John G. McHutchison7, Nancy Reau8, Keyur Patel9
1Johns Hopkins University, Baltimore, MD; 2James J. Peters VA Medical Center, Bronx, NY and Icahn School of Medicine at Mount Sinai, New York, NY; 3Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX; 4Liver Institute of Virginia, Richmond, VA; 5Kaiser Permanente, Los Angeles, CA; 6Ruane Medical, Los Angeles, CA; 7Gilead Sciences, Inc., Foster City, CA; 8Rush University Medical Center, Chicago, IL;
9University Health Network Liver Clinic, Toronto, Canada
|
| |
|
|
|
|
|
